Intellia Therapeutics Inc’s (NTLA) Stock: A Week-by-Week Analysis

The stock of Intellia Therapeutics Inc (NTLA) has gone down by -6.45% for the week, with a -23.15% drop in the past month and a -17.68% drop in the past quarter. The volatility ratio for the week is 5.01%, and the volatility levels for the past 30 days are 5.05% for NTLA.. The simple moving average for the past 20 days is -11.40% for NTLA’s stock, with a -22.61% simple moving average for the past 200 days.

Is It Worth Investing in Intellia Therapeutics Inc (NASDAQ: NTLA) Right Now?

Moreover, the 36-month beta value for NTLA is 1.80. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for NTLA is 93.89M and currently, short sellers hold a 14.38% of that float. On April 03, 2024, NTLA’s average trading volume was 1.57M shares.

NTLA) stock’s latest price update

Intellia Therapeutics Inc (NASDAQ: NTLA)’s stock price has gone decline by -7.79 in comparison to its previous close of 27.22, however, the company has experienced a -6.45% decrease in its stock price over the last five trading days. The Motley Fool reported 2024-03-28 that Cathie Wood added to her positions in these biotech stocks this week. The famous investor seeks out undervalued innovators to add to her funds and hold onto for the long term.

Analysts’ Opinion of NTLA

Many brokerage firms have already submitted their reports for NTLA stocks, with Goldman repeating the rating for NTLA by listing it as a “Neutral.” The predicted price for NTLA in the upcoming period, according to Goldman is $32 based on the research report published on February 23, 2024 of the current year 2024.

Canaccord Genuity gave a rating of “Buy” to NTLA, setting the target price at $66 in the report published on April 13th of the previous year.

NTLA Trading at -9.14% from the 50-Day Moving Average

After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.14% of loss for the given period.

Volatility was left at 5.05%, however, over the last 30 days, the volatility rate increased by 5.01%, as shares sank -22.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.76% lower at present.

During the last 5 trading sessions, NTLA fell by -6.45%, which changed the moving average for the period of 200-days by -44.47% in comparison to the 20-day moving average, which settled at $27.96. In addition, Intellia Therapeutics Inc saw -17.68% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at NTLA starting from BASTA JAMES, who sale 2,297 shares at the price of $32.99 back on Mar 04 ’24. After this action, BASTA JAMES now owns 81,571 shares of Intellia Therapeutics Inc, valued at $75,778 using the latest closing price.

Clark Eliana, the EVP, Chief Technical Officer of Intellia Therapeutics Inc, sale 605 shares at $32.99 during a trade that took place back on Mar 04 ’24, which means that Clark Eliana is holding 71,470 shares at $19,959 based on the most recent closing price.

Stock Fundamentals for NTLA

Current profitability levels for the company are sitting at:

  • -14.21 for the present operating margin
  • 0.75 for the gross margin

The net margin for Intellia Therapeutics Inc stands at -12.97. The total capital return value is set at -0.43. Equity return is now at value -42.10, with -34.11 for asset returns.

Based on Intellia Therapeutics Inc (NTLA), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -3.42.

Currently, EBITDA for the company is -506.21 million with net debt to EBITDA at 0.22. When we switch over and look at the enterprise to sales, we see a ratio of 63.43. The receivables turnover for the company is 1.0for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.67.

Conclusion

To wrap up, the performance of Intellia Therapeutics Inc (NTLA) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts